You Lu

13PUBLICATIONS
68CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Radiation therapyAvionics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jul 08, 2026
SBRT embedded in low-dose RT plus αPD-1 (immuno-EclipseRT, iERT) elicits CD8<sup>+</sup> T cell immunity against bulky tumors via an IFN-I/NK/DC axis.

|Oct 21, 2025
Drug allergy history predicts early progression-free survival benefit from PD-(L)1 inhibitors in advanced non-small cell lung cancer: a retrospective cohort study.

Wenhao Zhao, Min Yu, Youling Gong

|Apr 17, 2025
Dynamic evolution and antitumor mechanisms of CXCR6<sup>+</sup>CD8<sup>+</sup> T cells in small cell lung cancer treated with low-dose radiotherapy and immunotherapy.

Guo Lin, Zhuoran Yao, Kai Kang

|Jun 10, 2024
CDK4/6 inhibitor abemaciclib combined with low-dose radiotherapy enhances the anti-tumor immune response to PD-1 blockade by inflaming the tumor microenvironment in Rb-deficient small cell lung cancer.

Laduona Wang, Yijun Wu, Kai Kang

|Jan 05, 2024
Author Correction: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC.

Caicun Zhou, Ziping Wang, Meili Sun

|Aug 15, 2023
Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non-Small Cell Lung Cancer Patients.

Xiaojuan Zhou, Laiyan Zhou, Zhuoran Yao

Pageof 3

Frequent Collaborators

3 joint publications

Min Yu

3 joint publications

Jianxin Xue

3 joint publications

Kai Kang

2 joint publications

Zhuoran Yao